Immunomodulatory Effects of Galectin-1 on an IgE-Mediated Allergic Conjunctivitis Model

Immunomodulatory Effects of Galectin-1 on an IgE-Mediated Allergic Conjunctivitis Model

Autor Mello, Claudia Bosnic Google Scholar
Ramos, Lisandra Autor UNIFESP Google Scholar
Gimenes, Alexandre Dantas Autor UNIFESP Google Scholar
Andrade, Teresa Raquel de Moraes Autor UNIFESP Google Scholar
Oliani, Sonia Maria Autor UNIFESP Google Scholar
Gil, Cristiane Damas Autor UNIFESP Google Scholar
Instituição Univ Estadual Paulista
Universidade Federal de São Paulo (UNIFESP)
Resumo PURPOSE. Galectin (Gal)-1, a lectin found at sites of immune privilege with critical role in the inflammation, has been poorly investigated in the ocular inflammatory diseases. Here, we evaluated the therapeutic potential of Gal-1 in ocular allergy using a model of ovalbumin (OVA)-induced AC.METHODS. OVA-immunized BALB/c male mice were challenged with eye drops containing OVA on days 14 through 16 with a subset of animals pretreated intraperitoneally with recombinant Gal-1 (rGal-1) or dexamethasone (Dex).RESULTS. Recombinant Gal-1 and Dex administration on days 14 through 16 was effective in reducing the clinical signs of allergic conjunctivitis (AC), plasma anti-OVA IgE levels, Th2 (IL-4 and IL-13), and eotaxin/RANTES levels in the lymph nodes. Four hours after the last OVA challenge, rGal-1 markedly increased Gal-1 endogenous levels in the conjunctiva, and provoked eosinophilia, which persisted at 24 hours. Recombinant Gal-1 had no effect on eosinophil activation, as evidenced by the similar pattern of peroxidase eosinophil expression between cells of rGal-1-treated and untreated AC groups. Conjunctival migrated eosinophils and neutrophils exhibited high levels of Gal-1 and b2-integrin, with points of colocalization, in the rGal-1-treated groups. These different effects observed for rGal-1 were correlated with elevated levels of activated ERK and p38 at 4 hours, and diminished levels of activated JNK and p38 at 24 hours in the eyes.CONCLUSIONS. Gal-1 has an important role in ocular allergic inflammation and represents a potential target for the development of new therapeutic strategies in eye diseases.
Assunto eosinophil
beta 2-integrin
ocular allergy
Th2 cytokines
ultrastructural immunogold labelling
mitogen-activated protein kinases
Idioma Inglês
Financiador Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Número do financiamento FAPESP: 2011/21845-3
CNPq: 476136/2011-3
CNPq: 302768/2010-6
Data 2015-02-01
Publicado em Investigative Ophthalmology & Visual Science. Rockville: Assoc Research Vision Ophthalmology Inc, v. 56, n. 2, p. 693-704, 2015.
ISSN 0146-0404 (Sherpa/Romeo, fator de impacto)
Editor Assoc Research Vision Ophthalmology Inc
Extensão 693-704
Direito de acesso Acesso aberto Open Access
Tipo Artigo
Web of Science WOS:000352137300002

Mostrar registro completo

Arquivos deste item

Arquivos Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item aparece na(s) seguinte(s) coleção(s)